#USA #FieldForce™ #Cardiff-by-the-Sea #Field Medical #VCAS

Introduction

The recent publication in Circulation of the six-month results from the first-in-human Ventricular Catheter Ablation Study (VCAS) highlights significant findings regarding the FieldForce™ Ablation System developed by Field Medical, Inc. This novel system aims to address the challenges associated with ventricular tachycardia (VT) ablation, providing new hope for patients suffering from this serious condition.

Study Overview

The VCAS trial is a prospective multicenter feasibility study, evaluating the effectiveness and safety of the FieldForce™ Ablation System in patients with recurrent VT. This innovative approach utilizes a proprietary high-voltage, short-pulse waveform that is capable of penetrating dense scar tissue, which is often a significant obstacle in traditional ablation procedures. The trial results were presented during the 20th Annual International Symposium on Ventricular Arrhythmias, marking a notable point in cardiovascular innovation.

Key Findings

The outcomes from the six-month follow-up present an optimistically high percentage of patients experiencing freedom from VT following treatment. Notable findings include:

• - 82% Freedom from Recurrence: A significant 82% of patients reported freedom from recurrent VT or the need for implantable cardioverter-defibrillator (ICD) therapy.
• - 98% Reduction in VT Burden: The treatment led to a remarkable 98% reduction in the burden of VT episodes, showcasing the technology’s potential to transform patient experiences.
• - Safety Profile: The study reported that only 11.5% of participants experienced primary safety events, with no therapy-related complications emerging from the use of the System.

Dr. Vivek Reddy, a co-principal investigator and lead author from Mount Sinai, expressed cautious optimism regarding the initial results. “Achieving such high rates of freedom from recurrence and substantial reduction in arrhythmia burden with a nonthermal, tissue-selective energy approach is a meaningful accomplishment in treating VT,” he stated. This statement underscores the revolutionary impact such technology could have on the future of cardiology.

Clinical Implications

The findings from the VCAS trial present an important advance in the treatment of scar-related VT. Traditional energy sources have often struggled to create effective lesions within the dense scar tissue present in the heart’s ventricles. The FieldForce™ Ablation System appears to successfully navigate these challenges, offering hope for improved outcomes in a patient population that has faced limited options.

Field Medical has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA), propelling the advancement of this technology towards a pivotal trial. Such recognition from the FDA enhances its credibility, indicating the vital need for innovation in this area of cardiac care.

Future Directions

Looking ahead, Field Medical plans to explore the FieldForce™ Ablation System’s applications beyond ventricular tachycardia. Upcoming presentations at major scientific meetings will likely include an evaluation of initial feasibility findings in atrial fibrillation (AF). This branching out into other areas of cardiac arrhythmia treatment speaks volumes about the versatility and potential ripple effects of the technology.

Conclusion

In conclusion, the six-month outcomes from the VCAS trial represent a significant step forward in treating patients with ventricular arrhythmias. The encouraging data from this study highlight the potential of the FieldForce™ Ablation System to address an unmet need in the clinical landscape of cardiac care. As Field Medical continues to refine its technology and expand its applications, an impactful future for VT management appears promising, reiterating the importance of innovation in medicine.

About Field Medical, Inc.

Founded in 2022, Field Medical is dedicated to improving patient outcomes through advanced medical technology. The FieldForce™ Ablation System exemplifies their commitment to enhancing the safety and effectiveness of treatment for complex cardiac arrhythmias, particularly with its potential applications in both VT and AF management. Visit Field Medical for more details on ongoing advancements and future initiatives.